Download PDF
Exp Clin Endocrinol Diabetes 2006; 114(6): 295-300
DOI: 10.1055/s-2006-924265
Article

J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Improved Glycaemia in Type 1 Diabetes Results in Decreased Levels of Soluble Adhesion Molecules with No Change in Serum Adiponectin or Most Acute Phase Proteins

M. K. Heliövaara1 , A.-M. Teppo2 , S.-L. Karonen3 , J. A. Tuominen1 , P. Ebeling1
  • 1Division of Geriatrics, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
  • 2Division of Nephrology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
  • 3Department of Clinical Physiology, Helsinki University Central Hospital, Helsinki, Finland
Further Information

Publication History

Received: May 31, 2005 First decision: November 4, 2005

Accepted: May 9, 2006

Publication Date:
26 July 2006 (online)

Also available at
    Permissions and Reprints

Abstract

Aims: To investigate how reduction of hyperglycaemia affects acute phase serum proteins in poorly controlled type 1 diabetic patients. Methods: 24 patients (age 31.7 ± 2.0 years, HbA1c 9.3 ± 0.2 %, BMI 24.2 ± 0.7 kg/m2, diabetes duration 15.3 ± 1.7 years) participated in the study. The treatment was optimised for 16 weeks. Blood samples were taken at baseline and at the end of the study. 16 healthy age- and BMI-matched subjects were chosen for a control group. Results: At baseline, the patients had higher C-reactive protein (CRP) (1.09, median [range 0.24 - 18.82] mg/l vs. 0.66 [0.18 - 2.46] mg/l, p < 0.02), mean adiponectin (16.06 ± 1.31 vs. 8.85 ± 0.93 mg/l, p < 0.001), ceruloplasmin (306 ± 16.1 vs. 205.4 ± 5.5 mg/l, p < 0.001), fibrinogen (3.41 ± 0.26 vs. 2.38 ± 0.07 g/l, p < 0.001), soluble intercellular adhesion molecule-1 (sICAM-1) (255.4 ± 10.3 vs. 194 ± 10.6 µg/l, p < 0.001), soluble vascular adhesion molecule-1 (sVCAM-1) (533.4 ± 21.8 vs. 422.9 ± 20.7 µg/l, p < 0.01) and interleukin-6 (2.89 ± 0.49 vs. 1.35 ± 0.30 ng/l, p < 0.01) concentrations than the controls. During intensified treatment, HbA1c decreased (to 8.5 ± 0.2 %, p < 0.001). This resulted in reduced sE-selectin (from 44.6 ± 2.6 to 38.8 ± 2.6 µg/l, p < 0.01), α‐1-acid-glycoprotein (A1GP) (from 622.9 ± 47.9 to 525.7 ± 27.9 mg/l, p < 0.01), sICAM-1 (from 255.4 ± 10.3 to 240.8 ± 9.1 µg/l, p < 0.05) and IL-6 (from 2.9 ± 0.5 to 2.1 ± 0.4 ng/l, p < 0.01). Serum amyloid A (SAA) and CRP did not change 12.00 (0.7 - 222.0) vs. 12.00 (1.6 - 277.0) mg/l for SAA and 1.09 (0.24 - 18.82) vs. 1.09 (0.18 - 23.08) mg/l for CRP, baseline vs. treatment, respectively. Conclusions: Poorly controlled type 1 diabetic patients have increased values of adiponectin, CRP, ceruloplasmin, fibrinogen, sICAM-1, sVCAM-1 and IL-6. Reduction of hyperglycaemia results in decreased sE-selectin, A1GP, sICAM-1 and IL6, while other inflammatory factors including CRP, SAA and adiponectin are not affected.

Key words

Type 1 (insulin-dependent) diabetes mellitus - adiponectin - inflammation - soluble adhesion molecules - interleukin-6 - α1-acid glycoprotein

References

  • 1 Alexander R W. Inflammation and coronary artery disease.  N Engl J Med. 1994;  331 468-469
    CrossrefPubMedGoogle Scholar
  • 2 Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus.  BMJ. 1987;  294 1651-1654
    PubMedGoogle Scholar
  • 3 Breyer J A. Diabetic nephropathy in insulin-dependent patients.  Am J Kidney Dis. 1992;  20 533-547
    PubMedGoogle Scholar
  • 4 Brownlee M. Glycation and diabetic complications.  Diabetes. 1994;  43 836-841
    PubMedGoogle Scholar
  • 5 Cominacini L, Fratta Pasini A, Garbin U, Campagnola M, Davoli A, Rigoni A, Zenti M G, Pastorino A M, LoCascio V. E-selectin plasma concentration is influenced by glycaemic control in NIDDM patients: possible role of oxidative stress.  Diabetologia. 1997;  40 584-589
    CrossrefPubMedGoogle Scholar
  • 6 Cominacini L, Fratta Pasini A, Garbin U, Davoli A, De Santis A, Campagnola M, Rigoni A, Zenti M G, Moghetti P, LoCascio V. Elevated levels of soluble E-selectin in patients with IDDM and NIDDM: relation to metabolic control.  Diabetologia. 1995;  38 1122-1124
    PubMedGoogle Scholar
  • 7 Cosentino F, Hishikawa K, Katusic Z S, Lüscher T F. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells.  Circulation. 1997;  96 25-28
    PubMedGoogle Scholar
  • 8 Crook M A, Tutt P, Simpsom H, Pickup J C. Serum sialic acid and acute phase proteins in type 1 and type 2 diabetes mellitus.  Clin Chim Acta. 1993;  219 131-138
    CrossrefPubMedGoogle Scholar
  • 9 Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.  N Engl J Med. 1993;  329 977-986
    Google Scholar
  • 10 Ebeling P, Teppo A-M, Koistinen H A, Viikari J, Rönnemaa T, Nissén M, Bergkulla S, Salmela P, Saltevo J, Koivisto V A. Troglitazone reduces hyperglycaemia and selectively acute phase serum proteins in patients with type diabetes.  Diabetologia. 1999;  42 1433-1438
    CrossrefPubMedGoogle Scholar
  • 11 Elhadd T A, Kennedy G, Hill A, McLaren M, Newton R W, Greene S A, Belch J J. Abnormal markers of endothelial cell activation and oxidative stress in children, adolescents and young adults with type 1 diabetes with no vascular disease.  Diab/Metab Res Rew. 1999;  15 405-411
    CrossrefPubMedGoogle Scholar
  • 12 Fasching P, Veitl M, Rohac M, Streli C, Schneider B, Waldhausl W, Wagner O F. Elevated concentrations of circulating adhesion molecules and their associations with microvascular complications in insulin-dependent diabetes.  J Clin Endocrinol Metab. 1996;  81 4313-4317
    CrossrefPubMedGoogle Scholar
  • 13 Honkanen E, Grönhagen-Riska C, Teppo A-M, Maury C PJ, Meri S. Acute-phase proteins during hemodialysis: correlations with serum interleukin-1β levels and different dialysis membranes.  Nephron. 1991;  57 283-287
    PubMedGoogle Scholar
  • 14 Mannucci E, Ognibene A, Cremasco F, Dicembrini I, Bardini G, Brogi M, Terreni A, Caldini A, Messeri G, Rotella C M. Plasma adiponectin and hyperglycaemia in diabetic patients.  Clin Chem and Lab Medicine. 2003;  41 1131-1135
    PubMedGoogle Scholar
  • 15 Marfella R, Esposito K, Giunta R, Coppola G, De Angelis L, Farzati B, Paolisso G, Giuliano D. Circulating adhesion molecules in humans: role of hyperglycaemia and hyperinsulinemia.  Circulation. 2000;  101 2247-2251
    PubMedGoogle Scholar
  • 16 McMillan D E. Increased levels of acute-phase serum proteins in diabetes.  Metabolism. 1989;  38 1042-1046
    CrossrefPubMedGoogle Scholar
  • 17 Orchard T J, Dorman J S, Maser R E, Becker D J, Drash A L, Ellis D, LaPorte R E, Kuller L H. Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II.  Diabetes. 1990 a;  39 1116-1124
    PubMedGoogle Scholar
  • 18 Orchard T J, Dorman J S, Maser R E, Becker D J, Ellis D, LaPorte R E, Kuller L H, Wolfson Jr S K, Drash A L. Factors associated with avoidance of severe complications after 26 yr of IDDM. Pittsburgh Epidemiology of Diabetes Complications Study 1.  Diabetes Care. 1990 b;  13 741-747
    PubMedGoogle Scholar
  • 19 Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S. Novel modulator for endothelial adhesion molecules. Adipocyte-derived plasma protein adiponectin.  Circulation. 1999;  100 2473-2476
    CrossrefPubMedGoogle Scholar
  • 20 Parving H ‐H, Hommel E, Mathiesen E, Skott P, Edsberg B, Bahnsen M, Laurizen M, Hougaard P, Laurizen E. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes.  BMJ. 1988;  296 156-160
    CrossrefPubMedGoogle Scholar
  • 21 Pickup J C, Mattock M B, Chusney G D, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X.  Diabetologia. 1997;  40 1286-1292
    CrossrefPubMedGoogle Scholar
  • 22 Raitakari O T, Celermajer D S. Testing for endothelial dysfunction.  Ann Med. 2000;  32 293-304
    PubMedGoogle Scholar
  • 23 Schaffler A, Herfarth H, Paul G, Ehling A, Muller-Ladner U, Scholmerich J, Zietz B. Identification of influencing variables on adiponectin serum levels in diabetes mellitus type 1 and type 2.  Exp Clin Endocrinol Diabetes. 2004;  112 383-389
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Schalkwijk C G, Poland D CW, van Dijk W, Kok A, Emeis J J, Dräger A M, Doni A, van Hinsbergh V W, Stehouwer C D. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation.  Diabetologia. 1999;  42 351-357
    CrossrefPubMedGoogle Scholar
  • 25 The Complications Study Group E URODIABIDDM. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study.  Diabetologia. 1994;  37 278-285
    CrossrefPubMedGoogle Scholar
  • 26 Yudkin J S, Panahloo A, Stehouwer C, Emeis J J, Bulmer K, Mohammed-Ali V, Denver A E. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in type II diabetic subjects.  Diabetologia. 2000;  43 1099-1106
    CrossrefPubMedGoogle Scholar
  • 27 Yudkin J S, Stehouwer C DA, Emeis J J, Coppack S W. C-reactive protein in healthy subjects: associations with obesity, insulin resistance and endothelial dysfunction. A potential role for cytokines originating from adipose tissue?.  Arterioscl Thromb Vasc Biol. 1999;  19 972-978
    CrossrefPubMedGoogle Scholar

MD Maikki Heliövaara

Department of Medicine
Helsinki University Central Hospital

P. O. Box 340

00029 HUS

Finland

Phone: + 35 89 47 17 45 07

Fax: + 35 89 47 17 55 44

Email: maikki.heliovaara@hus.fi

      >